Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer, Medivation Alzheimer Drug Fails in Phase III | Contract Pharma

What are you searching for?

Sign in

Pfizer, Medivation Alzheimer Drug Fails in Phase III

Dimebon fails in CONNECTION trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Dimebon, an investigational drug co-developed by Pfizer and Medivation, failed its Phase III trial in Alzheimer’s disease. The compound failed to meet its co-primary and secondary efficacy endpoints — cognition and global function — compared to placebo in the CONNECTION trial. Dimebon was well-tolerated in its separate Phase III safety and tolerability study, when dosed alone or in combination with approved Alzheimer’s medicines.
“We are evaluating the CONNECTION data with Medivation. After that review, Pfizer will be in a position to determine appropriate next steps regarding the dimebon program,” said Dr. Briggs W. Morrison, senior vice president, clinical development, Primary Care Business Unit at Pfizer. “We recognize the significant medical need, and we are committed to advancing treatment options for Alzheimer’s disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters